Hisplex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hisplex

Property Description
Active ingredient Loratadine
Form Oral tablet, syrup, or suspension
Pharmacological class Second-generation H1-Antihistamine
Common use Systemic relief of allergic symptoms
Origin Synthetic compound (Piperidine derivative)

What Type of Medicine is Hisplex? (Definition and Classification)

Hisplex is an oral medicine containing the active ingredient Loratadine, which is classified as a synthetic, second-generation H1-Antihistamine. It functions as a selective histamine antagonist, providing systemic control over the physical manifestations of allergic reactions throughout the body.

The classification as a second-generation compound is pivotal. This compound is chemically designed for peripheral selectivity, meaning it does not readily cross the blood-brain barrier. This design supports its clinical recognition as a non-sedating agent, allowing it to effectively interrupt the allergic cascade while minimizing central nervous system effects.

Composition and Available Forms of Hisplex

The composition of this product is centered on the synthetic chemical compound Loratadine (C22H23ClN2O2), identified as a piperidine derivative. As a single active ingredient product (monotherapy), Hisplex’s purpose is derived entirely from this one substance. Loratadine is an established drug for its intended purpose.

For effective use via the oral route, the drug is supplied in various pharmaceutical preparations, including the solid oral tablet and liquid variants like an oral syrup or oral suspension. The availability of liquid forms is a key feature, ensuring adaptability for different patient groups, specifically aiding administration for children who may have difficulty swallowing the traditional oral tablet.

General Therapeutic Purpose of Loratadine

The overall general purpose of Hisplex is the control and relief of the systemic physical symptoms caused by allergic reactions. By acting as a selective histamine antagonist, the medicine targets the released histamine, the primary chemical mediator. This fundamental action is intended to relieve common manifestations, such as sneezing, itching of the nose and throat, and ocular irritation that often accompany a typical seasonal allergy exposure.

Regulatory References

  1. Loratadine: MedlinePlus Drug Information
  2. Loratadine Tablets, USP Antihistamine Drug Facts - DailyMed

What side effects are possible with Hisplex?

Possible Side Effects and Safety Information

The safety profile of Hisplex, which contains the active ingredient Loratadine, is established through regulatory documentation, classifying observed adverse reactions by frequency and the affected body system. The regulatory framework formally defines the risk profile, explicitly stating effects observed in clinical trials and post-marketing surveillance.


Official Adverse Reactions by Frequency and System

Adverse reactions are classified according to incidence. The most frequently reported reactions, categorized as Common (may affect up to 1 in 10 people), primarily involve the nervous system and general systemic issues. These include somnolence (drowsiness), headache, insomnia, and increased appetite in adults and adolescents, while headache, nervousness, and fatigue are common in children aged 2–12 years.

Reactions classified as Very Rare (may affect up to 1 in 10,000 people) span multiple physiological systems. These documented effects include hypersensitivity reactions (e.g., angioedema, anaphylaxis), convulsion, tachycardia (increased heart rate), palpitation, nausea, gastritis, and indicators of abnormal hepatic function. The symptom weight increased has also been documented with a frequency of Not Known.


Population-Specific Safety Notes and Constraints

Specific safety considerations are outlined in official labeling for certain patient groups. Individuals with severe hepatic impairment may experience reduced drug clearance, and regulatory authorities recommend a modified initial dosing regimen for this population. Caution is also noted for patients with renal impairment. Furthermore, the presence of aspartame in certain oral forms makes them a safety consideration for individuals with phenylketonuria (PKU).

To ensure procedural safety and accurate results, official labeling advises that administration should be discontinued at least 48 hours prior to allergy skin tests, as the drug may suppress expected dermal reactions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents outline the documented clinical manifestations and required emergency actions in the event of an overdose with the active ingredient Loratadine.

Overdose has been associated with specific clinical manifestations, including central nervous system effects such as somnolence (drowsiness) and headache. Cardiovascular effects, notably tachycardia (fast heart rate), have also been reported. The occurrence of anticholinergic symptoms is documented to increase in overdose situations. In children, specific reports of overdoses exceeding 10 mg of the syrup formulation have noted the appearance of extrapyramidal signs and palpitations.

Required Emergency Actions

In the event of a suspected overdose, regulatory guidance mandates that the patient must seek medical attention immediately or contact a Poison Control Center right away.

No specific antidote is known for Loratadine overdose. Management protocols described in regulatory documents require the institution of general symptomatic and supportive measures. Procedures such as gastric lavage or administration of activated charcoal as a slurry with water may be considered. Following emergency treatment, medical monitoring of the patient is to be continued.

Therapeutic Uses of Hisplex

What Hisplex Treats: Main Uses and Benefits

Hisplex is commonly used to help manage the core cluster of upper respiratory and ocular symptoms caused by seasonal or perennial allergies. This medicine is used in contexts where pronounced symptoms—such as persistent sneezing, runny nose, nasal itching, and itchy, watery eyes—create noticeable interference with daily stability. The medication provides supportive relief that assists with managing symptoms that interfere with daily comfort, including those related to allergic rhinitis and Chronic Urticaria.

It is relevant in clinical settings marked by allergic skin manifestations, helping manage symptom clusters like widespread pruritus (itching) and the associated development of welts or rash. This approach contributes to easing the overall symptom load during symptomatic periods.

“This medicine is commonly used to help with symptoms related to inflammatory or irritative states, supporting the patient during difficult episodes by easing physical discomfort.”

This medicine is relevant in contexts involving heightened systemic burden where preserving functional stability is appropriate. This offers symptomatic assistance, particularly for those seeking a non-sedating option for managing symptoms related to chronic or recurrent conditions.


Quick Fact: Relief for Pruritus and Hives Hisplex is relevant when addressing acute or episodic skin symptoms, and assists with managing symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus overview of Loratadine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Hisplex — Official Regulatory Information

The eligibility for Hisplex (Loratadine) is strictly defined by regulatory bodies, establishing age thresholds and absolute contraindications.

Eligibility Status Population Group
Established Use Adults and Adolescents (12 years and older); Children 6 years and older; Children 2 to 5 years (for approved liquid forms).
Contraindicated Patients with known hypersensitivity or allergy to loratadine or its components; Children younger than 2 years of age.

Condition-Specific Eligibility Rules Use is permitted only under restricted conditions for patients with severe hepatic impairment (liver failure) and severe renal impairment (kidney insufficiency, GFR < 30 mL/ min). Regulatory documentation requires a modified initial regimen, typically a reduced dose taken every other day. Individuals with Phenylketonuria (PKU) must also avoid certain formulations, such as chewable tablets, that contain phenylalanine.

Physiological Status Eligibility Official labeling states that use during lactation is not recommended because the medicine and its active metabolite are known to be excreted into breast milk. Use during pregnancy is generally considered acceptable in regulatory contexts.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Hisplex (Loratadine) as stated in government regulatory sources.

Pharmacokinetic Interactions Leading to Increased Exposure

Co-administration with specific medicinal products that inhibit hepatic metabolism can result in a pharmacokinetic interaction, officially leading to significantly increased plasma concentrations of Loratadine and its active metabolite. This outcome is classified as inhibition of clearance in regulatory documentation.

Interacting substances explicitly listed in regulatory labeling that cause this effect are:

  • Cimetidine
  • Erythromycin
  • Ketoconazole

Interactions with Food and Other Substances

Administration simultaneously with food is documented to cause a delay in the rate of absorption ( T max). However, regulatory findings state that this effect does not alter the overall extent of systemic exposure (AUC).

Official regulatory studies have specifically investigated the potential pharmacodynamic interaction with alcohol and documented no potentiation of its effects, indicating a low risk of additive central nervous system (CNS) depression.

Population-Specific Interaction Note

For patients with severe hepatic impairment, reduced clearance of Loratadine is expected. This condition may enhance the clinical significance and accumulation risk associated with co-administering any of the listed metabolic inhibitor medicines.

Mechanism of Action

Mechanism of Action: How Hisplex Works

Hisplex acts as a selective antagonist of the Histamine H1 receptor. The drug binds to this receptor, preventing the endogenous signaling molecule, histamine, from initiating its activity. This initial molecular interaction is responsible for interrupting the histamine signaling cascade primarily in peripheral tissues.

Blockade of the H1 receptor directly modulates the cellular processes that govern vascular dynamics. Specifically, the mechanism reduces the signaling instructions that lead to the widening of blood vessels (vasodilation) and increased gap formation between endothelial cells, which promotes the movement of fluid from the capillaries into the surrounding tissue (extravasation).

This targeted interference with the histamine pathway alters physiological parameters by reducing the level of activity in the targeted vascular responses. The result is a specific influence on tissue fluid levels and localized vascular diameter.

Dosage and Administration Information

How to Use Hisplex

Hisplex, containing Loratadine, is used according to a standardized, once-daily protocol. The medicine is exclusively for oral administration, available in multiple forms including tablets, oral solution, and rapidly disintegrating tablets.

Administration is generally straightforward and follows a fixed, non-titrated approach. The standard schedule requires the medicine to be taken once daily, reflecting its established 24-hour duration of action. Intake is permitted with or without food, providing flexibility for the user.

Official Dosing by Population

The dosage is fixed based on age for the treatment of common allergic conditions. These regimens are based directly on standard clinical guidelines:

Population Standard Dosing Regimen Maximum Recommended Frequency
Adults and Children 6 years 10 mg Once daily
Children 2 to under 6 years 5 mg Once daily

Special Procedural Conditions

Specific dosage adjustments are indicated for certain populations to prevent accumulation and align with established safety margins. For individuals with severe hepatic impairment or severe renal impairment (Glomerular Filtration Rate <30 mL/min), administration guidance involves the standard 10 mg dose being administered every other day.

When using liquid or syrup forms, the dose must be measured accurately using the device provided with the product. The use pattern for Hisplex is guided by the persistence of allergic symptoms, accommodating both short-term use for acute seasonal episodes and long-term use for chronic conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hisplex (Loratadine)

This section provides a factual overview of the clinical research conducted for Hisplex (Loratadine), detailing the types of studies available, the patient groups examined, and the overall consistency of the evidence relied upon by regulatory bodies.


Evidence for Use in Allergic Rhinitis

Research exploring the use of Hisplex for symptoms of allergic rhinitis (commonly known as hay fever) has utilized numerous short-term Randomized Controlled Trials (RCTs). This research design is used to explore the consistency of measured outcomes, focusing on physical discomfort such as sneezing, nasal itching, and watery eyes. Studies reported the measured values of these symptoms over defined time intervals when compared to inactive agents.

Scientific literature indicates that primary efficacy data is often based on short-term follow-up periods, typically two weeks or less, meaning long-term outcomes and maintenance effects are not as extensively characterized in the core RCTs. Furthermore, the scientific literature indicates variability in reported outcomes when different active antihistamines are compared in network analyses.


Evidence for Use in Chronic Urticaria

Research for Hisplex in chronic skin conditions, such as Chronic Urticaria (Hives), has been explored through short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused on outcomes capturing phases of heightened symptom activity, such as intense pruritus (itching) and the development of wheals (hives).

Scientific literature indicates its evidence is considered High level in this therapeutic context. Data for the long-term use of Hisplex in chronic urticaria are limited because most trials were conducted over short-term periods, typically lasting no more than six weeks. Additionally, research exploring different administration amounts in specific subgroups has limitations in the current scientific literature.


Research Limitations and Areas of Uncertainty

Studies have been conducted to evaluate Hisplex in Children and older adults. Evidence is derived from settings with varying symptom burdens, but data for certain comorbid groups, such as those with certain pre-existing conditions, are limited in core clinical trials. Comparative evidence in certain research contexts is lacking regarding how Hisplex may be associated with outcomes against other active agents.

Key Studies & References

  1. Loratadine and Desloratadine Use in Children (Pediatric Pharmacotherapy Review)
  2. Clinical Practice Guidelines: Urticaria (The Royal Children's Hospital/Standard Guidelines)

Frequently Asked Questions (FAQ)

Common questions about Hisplex (FAQ)


Q: How quickly does Hisplex usually start to work?

Studies and official information indicate that the onset of action for allergy symptom relief can generally begin within one to three hours after taking the medicine. The medicine has an established duration of action of approximately 24 hours.


Q: Does Hisplex cause changes in mood or sleep?

Official regulatory documents list side effects related to the nervous system. Insomnia (trouble sleeping) is listed as a common side effect in adults and adolescents. Additionally, nervousness is documented as a common side effect in children aged 2 to 12 years.


Q: Is it normal to feel slightly dizzy when first starting Hisplex?

Official patient information lists dizziness in the uncommon side effect category. This indicates that while it is not a frequently reported event, the effect is officially recognized in the product's safety profile.


Q: Does Hisplex have a black box warning?

Official labeling from the United States FDA does not include a Black Box Warning for Hisplex (Loratadine). This confirms the absence of this specific warning in the drug's regulatory documentation.


Q: Does Hisplex need special storage conditions?

Official guidance specifies that the medicine should be stored at Controlled Room Temperature. It must also be protected from extreme heat, moisture, and light to maintain the product’s quality and integrity.


Q: What happens if I miss a dose of Hisplex (non-directive question)?

The medicine is designed for a fixed, once-daily schedule, and the recommended frequency of one dose in 24 hours must not be exceeded. This fixed schedule sets the boundary for proper administration.


Q: Is Hisplex a sedative?

Hisplex is classified as a non-sedating antihistamine. The classification indicates the medicine is designed for peripheral selectivity, limiting effects on the central nervous system. However, somnolence (drowsiness) is still listed as a common side effect in official documents.


Q: Are there official guidelines for stopping Hisplex?

Official procedural guidelines require Hisplex to be discontinued at least 48 hours prior to an allergy skin test. For children aged 2 to 12, the regulatory use pattern is generally limited to short-term periods (no longer than 14 days).


Q: Are there common skin reactions associated with Hisplex?

Official regulatory documentation lists hypersensitivity reactions (which can involve the skin, such as rash or swelling) as a Very Rare adverse effect. Skin reactions that are not classified as hypersensitivity are not cited in the common or very rare adverse reaction categories.


Q: Is it possible to be allergic to Hisplex?

Official regulatory information states that the medicine is contraindicated (not appropriate for use) for patients with a known hypersensitivity or allergy to loratadine or its components.


Q: Can Hisplex affect the results of any lab tests?

Yes, official labeling advises that the medicine must be discontinued at least 48 hours prior to allergy skin tests. This is because the drug may suppress expected dermal reactions and potentially affect the accuracy of the results.


Q: Does Hisplex interact with herbal supplements like St. John's Wort?

Co-administration with enzyme-inducing substances, which include certain supplements like St. John’s wort, may potentially influence drug clearance enzymes. This influence can affect how the body processes the medication.


Q: How does the body get rid of Hisplex after I take it?

The medicine is extensively broken down (metabolized) in the body. Its components are primarily eliminated through excretion, with approximately 80% of the dose equally excreted via urine and feces.


Q: Are there any common misuses of Hisplex that people should know about?

Authoritative reviews on the drug class note that Hisplex should be used only for its officially approved purposes (relief of allergic symptoms). It is not indicated for other unapproved conditions, such as certain types of coughs or insomnia.


Q: What kind of safety surveillance is done on Hisplex after it is approved?

The medicine's safety profile is continuously tracked through post-marketing surveillance. This involves systematically collecting and analyzing reports of adverse drug reactions experienced by the general public after the medicine has received regulatory approval.


Q: Is there a maximum time Hisplex should be used?

Regulatory documents state that clinical evidence supports treatment for up to six months for adults. For children aged 2 to 12, the medication is generally intended for short-term use only (typically no longer than 14 days), unless the patient is under medical supervision.


Q: Do official documents mention any risk of overdose with Hisplex?

Official clinical resources provide information on overdose symptoms. These notes indicate that taking more than the recommended amount may result in a rapid heart rate (tachycardia), drowsiness, headache, or agitation.


Q: What is the main reason Hisplex is prescribed?

The general purpose of Hisplex is the control and relief of systemic physical symptoms caused by allergic reactions. This includes common manifestations such as sneezing, itching of the nose and throat, and ocular irritation.


Q: What does Hisplex do to my body?

Hisplex works at the molecular level as an H1-receptor antagonist. This means it interrupts the activity of the signaling molecule histamine, which then helps influence local vascular responses and reduces swelling caused by tissue fluid levels.


Q: How is Hisplex typically packaged?

Hisplex is supplied in various pharmaceutical preparations to suit different patient needs. These include solid oral tablets and liquid forms such as an oral syrup or oral suspension.


Q: Are there any long-term studies on the use of Hisplex?

The research evidence overview indicates that while the core data relies on numerous short-term Randomized Controlled Trials (RCTs), evidence on long-term outcomes and maintenance effects is not as extensively characterized in these initial core trials.


Q: Is Hisplex considered a 'controlled substance'?

Official government drug scheduling authorities do not classify Hisplex (Loratadine) as a controlled substance under the relevant federal acts.

How should Hisplex be stored and disposed of?

How to Store and Dispose of Hisplex?

Medication must be stored strictly according to the conditions defined in official regulatory documents. Hisplex should be stored in a location inaccessible to children and pets to prevent accidental ingestion. The general regulatory guidance for many drugs recommends storage at Controlled Room Temperature, protecting the product from extreme heat, moisture, and light.

For disposal of unused or expired Hisplex, the preferred method is to return it immediately to a recognized drug take-back program or pharmacy drop-off location. If a take-back option is unavailable, the product must be prepared for disposal in the household trash by removing it from the original container, mixing it with an undesirable substance (such as dirt or used coffee grounds), and placing the mixture in a sealed container. Before discarding the original packaging, all personal information on the label must be completely removed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hisplex found in:

A-Z Index: